Hepion: Rises on positive NASH drug data

Hepion Pharmaceuticals

29/12/2020 22:54

** Hepion  HEPA.O  shares up 8.2% at $2.25 after market as
drug developer reports positive data for its drug, CRV431, to
treat non-alcoholic steatohepatitis (NASH)
    ** Hepion says data from a group receiving low dose of
CRV431 in its mid-stage trial indicated it was generally safe
and well tolerated  urn:newsml:reuters.com:*:nACSdPDzja
    ** HEPA also says clinically significant reductions in
important indicators of disease were observed in 28 days
    ** NASH is a fatty liver disease that has no approved
treatments and is poised to become the leading cause of liver
transplants
    ** HEPA shares down about 61% YTD

 (Reporting by Praveen Paramasivam in Bengaluru)
 ((Praveen.Paramasivam@thomsonreuters.com))